Anticytosine therapy for primary myelodysplastic syndrome
Abdulkadyrov, K.M.; Gritsaev, S.V.; Bessmel'tsev, S.S.; Martynkevich, I.S.; Tiranova, S.A.; Blinov, M.N.; Osipova, R.I.
Voprosy Onkologii 49(4): 464-466
2003
ISSN/ISBN: 0507-3758 PMID: 14569938 Document Number: 559600
A pilot study of anticytocine therapy (PCD) was carried out in 9 patients with primary myelodysplastic syndrome (MDS). After 12 weeks, 2 patients (22%) showed hematological response cutting down the need for washed-out erythrocyte transfusions by half or more. MDS progression at different stages was reported in 4; transformation to acute myeloleukemia - 2. PCD treatment is indicated in MDS patients, aged over 65, with a less than 10% blast level of the bone marrow, and without any risks of tumor progression.